- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Sera Prognostics GAAP EPS of -$0.16 misses by $0.02, revenue of $0.04M misses by $0.03M | 1 | Seeking Alpha | ||
| Mi | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2026 Financial Results | 30 | PR Newswire | Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering TestPreTRM® test volume increases 54% sequentially and approximately five-fold... ► Artikel lesen | |
| Mi | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Mi | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Sera Prognostics names Scott Gleason as chief financial officer | 2 | Investing.com | ||
| 19.08. | Sera Prognostics appoints Scott Gleason as CFO, effective Aug. 31 | 1 | Seeking Alpha | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 19.08. | Sera Prognostics ernennt Scott Gleason zum neuen Finanzvorstand | 1 | Investing.com Deutsch | ||
| 19.08. | Sera Prognostics, Inc.: Sera Prognostics Appoints Scott Gleason Chief Financial Officer | 480 | PR Newswire | SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
| 12.08. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2026 Financial Results | 276 | PR Newswire | SALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 09.07. | Sera Prognostics study shows NICU admission cut in first births | 1 | Investing.com | ||
| 30.06. | Sera Prognostics adds former Myriad Genetics CEO to board | 1 | Investing.com | ||
| 30.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.06. | All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy | 1 | Zacks | ||
| 01.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2026 Financial Results | 903 | PR Newswire | SALT LAKE CITY, May 6, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing... ► Artikel lesen | |
| 18.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter And Full Year 2025 Financial Results | 582 | PR Newswire | SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 13.11.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2025 Financial Results | 1.109 | PR Newswire | SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,526 | +2,10 % | VALNEVA SE: Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026 | ||
| NANOREPRO | 1,630 | +1,56 % | EQS-News: NanoRepro AG: Operatives Ergebnis im ersten Halbjahr 2026 deutlich verbessert - newkee gemeinsam mit PAEDIPROTECT im deutschlandweiten Drogeriehandel präsent | EQS-News: NanoRepro AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
NanoRepro AG: Operatives Ergebnis im ersten Halbjahr 2026 deutlich verbessert - newkee gemeinsam mit... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 5,410 | +5,87 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,783 | +16,52 % | Ocugen, Inc. - 10-Q, Quarterly Report | ||
| VIKING THERAPEUTICS | 24,500 | +4,93 % | Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. | ||
| COSCIENS BIOPHARMA | 5,320 | +1,14 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,918 | +17,69 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,746 | +0,75 % | Biocryst outlines $415M-$425M 2026 operating expense guidance while keeping ORLADEYO at $625M-$645M | ||
| SAREPTA THERAPEUTICS | 16,640 | +0,36 % | Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,251 | +3,02 % | PacBio narrows 2026 revenue guidance to $155M-$160M while targeting cash flow breakeven in 2028 | ||
| IBIO | 0,733 | +0,34 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ET | ||
| ARBUTUS BIOPHARMA | 3,490 | +0,58 % | Arbutus Biopharma Corporation: Arbutus Announces Final Results of Its US$230 Million Modified "Dutch Auction" Tender Offer | WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,412 | +0,27 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| MANNKIND | 3,473 | +4,20 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,960 Euro und damit +1,55 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.